Posted by Michael Wonder on 29 Jan 2024
Celltrion USA completes submission of biologics license application for CT-P47, a biosimilar candidate of Actemra (tocilizumab)
28 January 2024 - The biologics license application for CT-P47 was based on Phase III data comparing CT-P47 to the reference product Actemra (tocilizumab).
Celltrion USA today announced the submission of biologics license application to the US FDA for CT-P47, a biosimilar candidate of the reference product Actemra (tocilizumab).
